Glaukos stock has delivered very strong gains over the last five years, yet the current valuation checks and market multiples suggest the shares now lean expensive rather than clearly cheap.

• Glaukos has returned 260.2% over the past 5 years, which puts extra focus on whether the current price still leaves enough room for a reasonable long term return.
• Expectations for continued growth in ophthalmology treatments can support today’s price, while any setback in execution or slower revenue progress may quickly put pressure on the valuation.
• Glaukos scores just 2 out of 6 on broader valuation checks, which points to a stock that screens as expensive rather than a clear bargain.

The issue now is whether Glaukos' recent performance justifies paying this richer valuation or whether the stock is pricing in too much optimism.

Does Glaukos Look Pricey on Sales?

P/S can be a useful way to think about Glaukos because the company is still loss making on free cash flow, so earnings based ratios are less informative. Here the headline number is punchy. Glaukos trades on a P/S of about 18.2x, compared with a Medical Equipment industry average of roughly 3.0x and a broader peer group near 4.2x. That is a very large premium to both its sector and similar stocks.

A tailored fair P/S ratio for Glaukos that factors in its profile comes out closer to 8.9x. Compared with the current 18.2x, the share price implies a much richer multiple than this model suggests is reasonable. This does not say Glaukos must fall, but it does indicate that the market already assigns a lot of value to its future revenue potential.

On the P/S multiple, Glaukos stock screens as clearly overvalued versus both its industry and a more tailored fair value benchmark.

The Glaukos Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Glaukos pick up where this valuation puzzle leaves off and explain what kind of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price. Each one presents a fair value as a clear thesis about Glaukos' business that you can monitor over time, rather than just a one-off snapshot, and they sit on Simply Wall St's Community page.

Glaukos attracts sharply different views, with some investors focused on the product runway and others fixated on how much optimism is already in the price.

Bull case: roughly fairly valued

"Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies..."

Bear case: 39% overvalued

"Persistent and intensifying downward pressure on healthcare reimbursement, particularly in the U.S., threatens to erode Glaukos' pricing power..."

Do you think there's more to the story for Glaukos? Head over to our Community to see what others are saying!

The Bottom Line

Glaukos looks overvalued on market multiples, with the P/S premium suggesting a lot of future success is already reflected in the share price. The broader valuation checks also lean weak, which means there is limited margin for error if growth, adoption or pricing fall short of optimistic expectations. For you as an investor, the key question is whether Glaukos can deliver the revenue scale and profitability that would keep this rich multiple intact instead of drifting back toward industry norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.